KB220ZTM a Pro-Dopamine Regulator Associated with the Protracted, Alleviation of Terrifying Lucid Dreams. Can We Infer Neuroplasticity-induced Changes in the Reward

Thomas McLaughlin1, Marcelo Febo2, Rajendra D. Badgaiyan3, Debmalya Barh4, Kristina Dushaj5, Eric R. Braverman5, Mona Li5, Margaret A. Madigan6 and Kenneth Blum2, 4-12* 1Center for Psychiatric Medicine, North Andover, MA, USA 2Department of Psychiatry and McKnight Brain Institute, University of Florida, College of Medicine, Gainesville, FL, USA 3Molecular and Functional Imaging Laboratory, Department of Psychiatry, University of Minnesota, Minneapolis, MN, USA; Neuromodulation Program, University of Minnesota Twin City Campus, Minneapolis, MN, USA; Laboratory of Advanced Radiochemistry, University of Minnesota Twin City Campus, Minneapolis, MN, USA 4Centre for Genomics and Applied Gene Technology, Institute of Integrative Omics and Applied Biotechnology (IIOAB), Nonakuri, Purba Medinipur, India 5Department of Clinical Neurology, PATH Foundation NY, New York, NY, USA 6Department of Personalized Medicine, IGENE, LLC., Austin, TX, USA 7Community Mental Health Institute, Center for Clinical & Translational Science, University of Vermont and Department of Psychiatry, University of Vermont College of Medicine, Burlington, VT, USA 8Division of Addiction Services, Dominion Diagnostics, LLC., North Kingstown, RI, USA 9Division of Neuroscience-Based Therapy, Summit Estate Recovery Center, Los Gatos, CA, USA 10Department of Nutrigenomics, LaVita RDS, LLC, Salt Lake City, UT, USA 11Division of Neuroscience Research & Addiction Therapy, Shores Treatment & Recovery Center, Port Saint Lucie, FL, USA 12Department of Education & Psychology, Eotvus Lorand University, Budapest, Hungary